Revelation Biosciences, Inc. cash flow to debt ratio of -1.11K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Revelation Biosciences, Inc.'s free cash flow has increased -54.91% from $-18.34M last year to $-8.27M, signaling increasing performance

Revelation Biosciences, Inc.'s debt to equity ratio is 0.07, which means that the company's assets are healthy financed, signaling financial stability.

Revelation Biosciences, Inc. has insufficient data to evaluate this check.

Revelation Biosciences, Inc. has a net cash position, so leverage is healthy.

Interest expense is not separately reported in Revelation Biosciences, Inc.'s latest filing, so interest coverage cannot be calculated.

Revelation Biosciences, Inc. has insufficient data to evaluate this check.

Revelation Biosciences, Inc.'s short-term assets of $10.81M exceed its short-term liabilities of $2.00M

Revelation Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Revelation Biosciences, Inc.'s return on equity of -100.20%, is lower than 15.00%, indicating bad performance

Revelation Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Revelation Biosciences, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Revelation Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Revelation Biosciences, Inc. has negative free cash flow, indicating cash burn

Revelation Biosciences, Inc.'s yearly earnings has increased -40.73% since last year from $-15.04M to $-8.91M, signaling increasing performance

Revelation Biosciences, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -104.28% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Revelation Biosciences, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Revelation Biosciences, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Revelation Biosciences, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Revelation Biosciences, Inc. is overvalued relative to its fair value price of 0.52 based on Discounted Cash Flow model

Revelation Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Revelation Biosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Revelation Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Revelation Biosciences, Inc. has insufficient data to evaluate this check.

Revelation Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Revelation Biosciences, Inc. has a price-to-book ratio of 0.43x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Revelation Biosciences, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue